Bristol-Myers Squibb presented data at the WCBP which demonstrated thatSerzone (nefazodone) is effective in the treatment of severely-depressed hospitalized patients.
81 patients received either Serzone (100-600mg/day) or placebo for a period of six weeks. Serzone was found to be superior to placebo on the Hamilton Depression Rating Scale, with a mean change of 13.5 in Serzone-treated patients, and 6.1 in placebo receivers. The number of patients experiencing at least a 50% decrease in the HAM-D score was 54% of the Serzone group versus 18% of the placebo group. Significant differences were noted by week one on a number of rating scales.
Of the Serzone-treated group, 10% discontinued due to side effects versus 13% of the placebo group. In addition, 29% of Serzole receivers and 48% of those taking placebo discontinued due to lack of clinical effect.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze